Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Standard view
Full view
of .
Look up keyword
Like this
0 of .
Results for:
No results containing your search query
P. 1


Ratings: (0)|Views: 75 |Likes:
Published by Bryan Nicoll

More info:

Published by: Bryan Nicoll on Oct 25, 2011
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less





New product labels
As 2003 gets off to a start,Lohmann AnimalHealth International is launching a “new look”in the United States market with our newlydesigned LAH labels,which symbolize ourcompany’s relationship with Lohmann AnimalHealth. We have nearly completed our trans-formation from the dual company that func-tioned as Vineland/MBL,and we have growninto our own as Lohmann Animal HealthInternational. As a part of Lohmann AnimalHealth,we stand for quality products and serv-ices and a sincere dedication to the poultryindustry. We have structured ourselves to bevery lean and productive,exactly like ourpoultry production customers.The new labels carry our LAHI corporate nameat the bottom,our Gainesville,Ga.,headquar-ters address,and our recently approved singleUSDA Establishment Number. All of the infor-mation is framed by a colorful stripe down theleft side of the label. Look for them when youget your next vaccine shipment.These new labels will now be submittedto international regulatory officials toupdate our product registrations in morethan 60 countries. It will take more thana year to complete this phase of labelintroduction.
Production consolidation streamlinesoperations
We are in the final phase of consolidating allU.S. vaccine production to our recently mod-ernized site in Maine. With production facili-ties in Maine and Cuxhaven,Germany,wecan easily accommodate the growing globalvaccine production needs for our company.The exception to this approach is the produc-tion of Marek’s vaccine,which,for the imme-diate future,will continue to be made at ourNew Jersey facility. We are in the final stagesof completely revamping people,processes,facilities and materials to improve our abilityin this major product area. We have runvalidation serials and are now entering themarket with more consistent Marek’s vaccines.We intend to be a long-term supplier of thebest Marek’s vaccines in the world,and ourvolume capabilities will continue to buildthrough 2003.
Inactivated vaccines are the core of oursuccess
We are the global leader in inactivated vac-cines. Our success lies in our unique adjuvantapproaches,our individualized serviceapproach with autogenous vaccines in the U.S.and in Germany,and our enhanced vaccineproduction capabilities with our state-of-the-art,fully automated plant in Maine.As an example of this,the popularity of ourbroiler breeder vaccine,BTO2-REO,is grow-ing in the U.S. broiler business. Its 100 per-cent bursa-derived IBD antigen is coupledwith the industry leader in REO formulation.This vaccine is perfect to protect young broil-ers and allow them to produce up to theirgenetic capacity. Ask your LAHI area manag-er for a visit from our technical support groupto program BTO2-REO into your operation.And,while you’re at it,include a trial withFC4 Gold™,the low dose,intramuscularlyapplied Fowl Cholera vaccine with a specialadjuvant designed for 21st century breeders.
 from the president…
V.1 2003
  a  v  i  a  n  i  n  s  i  g  h  t
  F  o  r  f  u  r  t  h  e  r i  n  f  o  r   m  a  t i  o  n :  7  7  0 .  5  3  2 .  3  6  2  7  •  8  0  0 .  6  5  5 .  1  3  4  2  •   w   w   w . l  a  h i  n  t  e  r  n  a  t i  o  n  a l .  c  o   m
  1  1  4  6   A i  r  p  o  r  t   P  a  r  k   w  a  y    G  a i  n  e  s  v i l l  e ,   G   A  3  0  5  0  1
 Avian Insight winter 2003 3/7/05 2:24 PM Page 1
 Extracted from a presentation “Evaluationof the effect of heating an oil emulsionPasteurella multocida bacterin on tissuereaction and immunity.”Karen E. Burns,Jaime Ruiz,and John R.Glisson. Poultry Diagnostic and ResearchCenter,University of Georgia. Presented at  AAAP,2001 Boston.
Oil emulsion inactivated vaccines are criticalcomponents of vaccination programs for long-lived birds,i.e. breeders,layers and turkeys.These vaccines provide a long duration of immunity and improve antibody response forbreeders in order to provide protective mater-nal antibodies to progeny.Common injection sites include subcutaneous-ly (S.Q.) in the back of the neck,ventral sideof the tail,and intramuscularly (I.M.) in thebreast,thigh,or leg. However,there are inher-ent problems in all of the above vaccinationtechniques. For example,the S.Q. neck injec-tion offers the highest risk for accidentalhuman injection,a medical emergency.Commonly,a deeper injection into the musclesof the neck occurs,resulting in pain,feedrefusal,and cull birds.Oil emulsion bacterins tend to be the mostreactive when injected into the muscle. The tis-sue reaction can result in a greater incidence of condemnations at processing,further decreas-ing the low monetary return from spent hens.In order to examine a field solution to theproblem of I.M. injection reaction,a simpleinvestigation was completed at the Universityof Georgia to determine if heating the vaccinewould reduce the reaction in the breast muscle.Personal communication from an industry vac-cination crew indicated that they were heatingan oil emulsion bacterin in a water bath priorto I.M. injection into the breast. It is knownthat heating an oil emulsion decreases the vis-cosity of the vaccine. In theory,by adjustingthe vaccine closer to the birds’body tempera-ture,the vaccine may be less likely to leave alesion at processing,possibly because of morerapid absorption of the vaccine. Comparingthe heated vaccine to room temperature vac-cine allowed evaluation of a commonly usedfield technique and label recommendation.
Materials and Methods
The study used a commercially prepared
bacterin containing serotypes 1,3,and 4 from the same serial and lot,refrigerateduntil use. The heat treatment was performedby placing the bottle in a microbiologicalincubator set to 41 C (105
F) for five hoursbefore vaccination. The vaccine was placed
avian insight
Warming oil emulsion bacterins prior to injection
continued on page 2Warming oil emulsion bacterins prior to injection . . . . . . . . . . . . .
From the president . . . . . . . . . . . . .
V.1 2003
In this issue of avian insight:
Karen E. Burns, D.V.M,M.A.M,diplomate A.C.P.V Technical ServicesVeterinarian Lohmann Animal HealthGainesville,GA
Lesion in neck muscle of breeder pullet following improper injection technique of an oil emulsion vaccine Right and Left indicate side of the breast muscle where injection occurred.Groups were divided at 24 weeks, 1/2 challenge and 1/2 lesion scored.
# ofGroupBirds10 week18 week24 wee
HeatedVaccineRoom TempVaccineControls505050Vaccination - RightSerologyVaccination - RightSerologySerology OnlyVaccination – LeftSerologyVaccination – LeftSerologySerology OnlyChallenge & Serology (25 birds)Lesion Score (25)Challenge & Serology (25 birds)Lesion Score (25)Challenge & Serology (25 birds)Lesion Score (25)
Table 1:Study Organization
 Avian Insight winter 2003 3/7/05 2:25 PM Page 2
in a foam-insulated container for transport topens for immediate injection. Room tempera-ture vaccine was placed out of refrigeration for12 hours and allowed to warm to room tempera-ture. The birds were injected intramuscularly inthe superficial pectoral muscle with 0.5 mL of the bacterin using an 18-gauge 1/4 inch needle.Antibodies to
P. multocida
were measuredusing the IDEXX ELISA for
P. multocida
.25 birds from each treatment group were chal-lenged at 24 weeks of age with 1.0 mLserotype 1
P. multocida
(X-73 challenge strain,2.0 X 10
colony forming unit/mL) by I.M.injection in the left thigh.
Lesion Scoring.
25 birds from each treatmentgroup were euthanized at 24 weeks of age.Both breast muscles were carefully incised toreveal the superficial and deep pectoral mus-cles. The following scoring system was used tosubjectively evaluate the injection lesions:
V.1 2003
continued from page 1
0 = no visible lesions 2 = small multifocal lesions of < 1cm in diameter, same muscle layer; 3 = large focal or multifocal lesions > 1cm in diameter,including lesions that extended into deeper muscle layer 4 = abscessation, deep pectoral myopathy, lesions that were diffuse, > 5cm in diameter 1 = small focal lesion within one muscle layer, < 1cm in diameter 
continued on page 3
 Avian Insight winter 2003 3/7/05 2:25 PM Page 3

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->